Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Solid TumorsAdvanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 408
- Registration Number
- NCT05836324
- Locations
- 🇮🇹
Centro Ricerche Cliniche Di Verona, Verona, Italy
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
- Conditions
- Prurigo Nodularis
- Interventions
- Drug: Vehicle Cream
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 190
- Registration Number
- NCT05764161
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Pisana - Ospedale S. Chiara, Pisa, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy
🇰🇷Korea University Anam Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
- Conditions
- Prurigo
- Interventions
- Drug: Vehicle Cream
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 204
- Registration Number
- NCT05755438
- Locations
- 🇩🇪
Universitaetsklinikum Carl Gustav Carus Tu Dresden, Dresden, Germany
🇩🇪Universitatsklinikum Schleswig Holstein, Kiel, Germany
🇩🇪Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, Mainz, Germany
A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
- Conditions
- Nonsegmental Vitiligo With Genital Involvement
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 49
- Registration Number
- NCT05750823
- Locations
- 🇺🇸
Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, United States
🇨🇦Research Toronto, Toronto, Ontario, Canada
🇺🇸Center For Dermatology Clinical Research, Inc, Fremont, California, United States
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
- Conditions
- Graft-versus-host Disease (GVHD)
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05722912
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 47
- Registration Number
- NCT05696392
- Locations
- 🇺🇸
First Oc Dermatology, Fountain Valley, California, United States
🇺🇸Ark Clinical Research, Long Beach, California, United States
🇺🇸Gw Training Center, Washington, District of Columbia, United States
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Vehicle cream
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 69
- Registration Number
- NCT05635838
- Locations
- 🇺🇸
Revival Research Institute, Llc Troy, Troy, Michigan, United States
🇺🇸International Clinical Research Tennessee Llc, Murfreesboro, Tennessee, United States
🇺🇸Dermatology Associates of Plymouth Meeting, Plymouth Meeting, Pennsylvania, United States
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 43
- Registration Number
- NCT05624723
- Locations
- 🇩🇪
Apex Gmbh, Munich, Germany
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT05624710
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Texas Liver Institute Tli the Liver Institute of South Texas List Downtown Office, San Antonio, Texas, United States
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 608
- Registration Number
- NCT05620823
- Locations
- 🇺🇸
Investigative Site US303, Phoenix, Arizona, United States
🇺🇸Investigative Site US335, Arkansas, Arkansas, United States
🇺🇸Investigative Site US315, Laguna Niguel, California, United States